Description

The global HCAI control market is poised to grow by US$ 15.1 billion from 2022 to 2028, registering a CAGR of 8.1% during the forecast period, according to StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for HCAI control. The global HCAI control market is segmented on the basis of type, and region. By type, the global HCAI control market has been segmented into environment sterilization, medical devices, pharmaceuticals. According to the research, the environment sterilization segment had the largest share in the global HCAI control market. In terms of geography, the global HCAI control market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). In 2021, North America made up the largest share of revenue generated by the HCAI control market.

The medical devices market is further segmented into coated catheters, coated endotracheal tubes (ETTs), and intravenous (IV) filters. StrategyHelix research indicates that the coated catheters segment occupied the largest share of this market in 2021 and is expected to draw the highest demand in coming years. Furthermore, the pharmaceuticals market has been categorized into antibiotics, antifungals, antivirals, and vaccines. Globally, the antibiotics segment made up the largest share of the HCAI control market. The environment sterilization market is further divided into disinfectants, environment sterilization, and skin preparation. The disinfectants segment was the largest contributor to the global HCAI control market in 2021.

The global HCAI control market is highly competitive. Top players covered in Global HCAI Control Market Study are 3M Company, Bactiguard Holding AB, Becton Dickinson and Company (BD), Belimed AG, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Seqirus Inc., Teleflex Incorporated, The Clorox Company. Competitive landscape gives a description of the competitive nature of the global HCAI control market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the HCAI control market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: environment sterilization, medical devices, pharmaceuticals
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: 3M Company, Bactiguard Holding AB, Becton Dickinson and Company (BD), Belimed AG, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Seqirus Inc., Teleflex Incorporated, The Clorox Company

Key Benefits for Stakeholders

– Get a comprehensive picture of the global HCAI control market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. HCAI control market overview
Part 3. Market breakdown by type
– Environment sterilization
– Medical devices
– Pharmaceuticals
Part 4. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 5. Key companies
– 3M Company
– Bactiguard Holding AB
– Becton, Dickinson and Company (BD)
– Belimed AG
– F. Hoffmann-La Roche AG
– Gilead Sciences, Inc.
– Merck KGaA
– Novartis AG
– Pfizer, Inc.
– Sanofi S.A.
– Seqirus Inc.
– Teleflex Incorporated
– The Clorox Company
About StrategyHelix
Disclaimer